Teni Boulikas

Summary

Affiliation: Regulon A.E
Country: USA

Publications

  1. ncbi Clinical overview on Lipoplatin: a successful liposomal formulation of cisplatin
    Teni Boulikas
    Regulon, Inc, 715 N Shoreline Blvd, Mountain View, CA 94043, USA
    Expert Opin Investig Drugs 18:1197-218. 2009
  2. ncbi Systemic Lipoplatin infusion results in preferential tumor uptake in human studies
    Teni Boulikas
    Regulon, Inc, 715 North Shoreline Blvd, Mountain View, California 94043, USA
    Anticancer Res 25:3031-9. 2005
  3. ncbi Low toxicity and anticancer activity of a novel liposomal cisplatin (Lipoplatin) in mouse xenografts
    Teni Boulikas
    Regulon, Inc, Mountain View, CA 94043, USA
    Oncol Rep 12:3-12. 2004
  4. ncbi Recent clinical trials using cisplatin, carboplatin and their combination chemotherapy drugs (review)
    Teni Boulikas
    Regulon, Inc, Mountain View, CA 94043, USA
    Oncol Rep 11:559-95. 2004
  5. ncbi Cisplatin and platinum drugs at the molecular level. (Review)
    Teni Boulikas
    Regulon, Inc, Mountain View, CA 94043, USA
    Oncol Rep 10:1663-82. 2003
  6. ncbi Low renal toxicity of lipoplatin compared to cisplatin in animals
    Prasad Devarajan
    Nephrology and Hypertension, Cincinnati Children s Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH 45229, USA
    Anticancer Res 24:2193-200. 2004
  7. ncbi Pharmacokinetics and adverse reactions of a new liposomal cisplatin (Lipoplatin): phase I study
    George P Stathopoulos
    Errikos Dunant Hospital and Medical School of Athens, Athens, Greece
    Oncol Rep 13:589-95. 2005
  8. ncbi MLH1-deficient tumor cells are resistant to lipoplatin, but retain sensitivity to lipoxal
    Andre Fedier
    Department of Gynecology, University Hospital of Zurich, Zurich, Switzerland
    Anticancer Drugs 17:315-23. 2006
  9. ncbi Liposomal cisplatin combined with gemcitabine in pretreated advanced pancreatic cancer patients: a phase I-II study
    George P Stathopoulos
    Errikos Dunant Hospital and Medical School of Athens, Greece
    Oncol Rep 15:1201-4. 2006
  10. ncbi Liposomal oxaliplatin in the treatment of advanced cancer: a phase I study
    George P Stathopoulos
    First Oncology Department Errikos Dunant Hospital, Athens, Greece
    Anticancer Res 26:1489-93. 2006

Detail Information

Publications12

  1. ncbi Clinical overview on Lipoplatin: a successful liposomal formulation of cisplatin
    Teni Boulikas
    Regulon, Inc, 715 N Shoreline Blvd, Mountain View, CA 94043, USA
    Expert Opin Investig Drugs 18:1197-218. 2009
    ..Phase II studies are continuing in advanced breast cancer with vinorelbine and gastrointestinal cancers with radiotherapy and 5-fluorouracil. The highlights of the clinical development of Lipoplatin are reviewed...
  2. ncbi Systemic Lipoplatin infusion results in preferential tumor uptake in human studies
    Teni Boulikas
    Regulon, Inc, 715 North Shoreline Blvd, Mountain View, California 94043, USA
    Anticancer Res 25:3031-9. 2005
    ..In this respect, Lipoplatin emerges as a very promising drug in the arsenal of chemotherapeutics...
  3. ncbi Low toxicity and anticancer activity of a novel liposomal cisplatin (Lipoplatin) in mouse xenografts
    Teni Boulikas
    Regulon, Inc, Mountain View, CA 94043, USA
    Oncol Rep 12:3-12. 2004
    ..The preclinical studies reported here set the foundation for the clinical use of Lipoplatin as an exciting new drug with lower toxicity than cisplatin, endowed with proapoptotic properties...
  4. ncbi Recent clinical trials using cisplatin, carboplatin and their combination chemotherapy drugs (review)
    Teni Boulikas
    Regulon, Inc, Mountain View, CA 94043, USA
    Oncol Rep 11:559-95. 2004
    ..A preferential tumor targeting of chemotherapy treatments would bring a revolution in molecular medicine and would greatly advance cancer therapy in the upcoming years...
  5. ncbi Cisplatin and platinum drugs at the molecular level. (Review)
    Teni Boulikas
    Regulon, Inc, Mountain View, CA 94043, USA
    Oncol Rep 10:1663-82. 2003
    ..Particularly important are combinations of platinum drug treatments with other drugs, radiation and the emerging gene therapy regimens...
  6. ncbi Low renal toxicity of lipoplatin compared to cisplatin in animals
    Prasad Devarajan
    Nephrology and Hypertension, Cincinnati Children s Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH 45229, USA
    Anticancer Res 24:2193-200. 2004
    ..This is proposed as one mechanism to explain the low renal toxicity of Lipoplatin...
  7. ncbi Pharmacokinetics and adverse reactions of a new liposomal cisplatin (Lipoplatin): phase I study
    George P Stathopoulos
    Errikos Dunant Hospital and Medical School of Athens, Athens, Greece
    Oncol Rep 13:589-95. 2005
    ..Urine excretion reached about 40% of the infused dose in 3 days. The data demonstrate that Lipoplatin up to a dose of 125 mg/m2 every 14 days has no nephrotoxicity and it lacks the serious side effects of cisplatin...
  8. ncbi MLH1-deficient tumor cells are resistant to lipoplatin, but retain sensitivity to lipoxal
    Andre Fedier
    Department of Gynecology, University Hospital of Zurich, Zurich, Switzerland
    Anticancer Drugs 17:315-23. 2006
    ..However, this does not seem to apply to lipoxal, a novel liposomal formulation of oxaliplatin, because MLH1-deficient cells were as sensitive to lipoxal as MLH1-proficient cells...
  9. ncbi Liposomal cisplatin combined with gemcitabine in pretreated advanced pancreatic cancer patients: a phase I-II study
    George P Stathopoulos
    Errikos Dunant Hospital and Medical School of Athens, Greece
    Oncol Rep 15:1201-4. 2006
    ..3%). Liposomal cisplatin is a non-toxic alternative agent to bare cisplatin. In combination with gemcitabine, it has an MTD of 100 mg/m2 and shows promising efficacy in refractory pancreatic cancer...
  10. ncbi Liposomal oxaliplatin in the treatment of advanced cancer: a phase I study
    George P Stathopoulos
    First Oncology Department Errikos Dunant Hospital, Athens, Greece
    Anticancer Res 26:1489-93. 2006
    ..Our objectives were to determine the adverse reactions, dose-limiting toxicity (DLT) and the maximum tolerated dose (MTD) of lipoxal...
  11. ncbi Viral and non-viral vectors in gene therapy: technology development and clinical trials
    Kenneth Lundstrom
    Regulon Inc BioXtal, Chemin des Croisettes 22, CH 1066, Epalinges, Swizerland
    Technol Cancer Res Treat 2:471-86. 2003
    ..We propose that combinations of viruses with liposomes or polymers will solve the problem of systemic viral delivery and tumor targeting, bringing a revolution in molecular medicine and in applications of gene therapy in humans...
  12. ncbi Potential of the Akt inhibitor LY294005 to antagonize the efficacy of Cisplatin against HCT116 tumor cells in a DNA mismatch repair-dependent manner
    Andre Fedier
    Department of Gynecology, University Hospital of Zurich, CH 8091 Zurich, Switzerland
    Int J Oncol 29:1303-10. 2006
    ..g. a common target for both pathways. A possibly novel property of Akt in aggravating drug sensitivity may also be proposed...